Fundraising FoxBiotechnology Value Fund — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)Bruce Peacock(Director)
Co-investorsAvego BioScience CapitalHealthCapAgent CapitalCowen Healthcare InvestmentsJohnson & Johnson Innovation – JJDCNorthpond Ventures
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsLifelinkMPM BioImpactPfizer Venture InvestmentsMirae Asset Venture InvestmentPfizer VenturesPolaris Partners+1 more
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)
BoardMaha Katabi(Director)inPerry Nisen(Executive Officer, Director)inMaria Fardis(Director)inRajul Jain(Director)in
Co-investorsFinchley Healthcare VenturesLongitude CapitalSofinnova VenturesVida VenturesFrazier Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.